Kit for treating burns

Abstract

The present invention relates to a kit for treating burns, and more specifically, to a kit for treating burns that is easy to use and has excellent burn treatment effects. To this end, the kit for treating burns is characterized by separately containing component A, which includes isocyanate; and component B, which includes polyol and aluminum hydroxide.

Description

Technology Field

[0001] The present invention relates to a kit for burn treatment, and more specifically, to a kit for burn treatment that is easy to use and has excellent burn treatment effects. Background Technology

[0002] Burns are classified under injury and poisoning in the International Classification of Causes of Death. They occur relatively frequently in daily life; compared to chronic diseases, they occur more often in young and middle-aged adults who are highly active, and depending on the severity, they can lead to death. Although the mortality rate from burns has significantly decreased compared to the past due to advancements in burn treatment, the pain experienced by burn patients during treatment is considered the most severe among pains caused by other traumas, leading patients to experience extreme anxiety. Furthermore, skin burns cause severe edema and lead to ischemic damage due to decreased intravascular hydrostatic pressure resulting from increased vascular permeability. Additionally, burn tissue presents difficulties, such as the need for skin grafting in cases of partial-thickness or full-thickness burns. Burns are classified according to the depth of tissue damage: first-degree burns involve damage to only the epidermis; second-degree burns involve damage to the entire epidermis and most of the dermis; and third-degree burns involve damage to the entire epidermis, dermis, and subcutaneous fat layer. When a burn occurs, inflammatory mediators such as prostaglandins, histamine, and reactive oxygen species are released from the damaged tissue; in severe cases, immune function is compromised, increasing the risk of infection. Burn healing can be promoted by using dressings. An ideal burn dressing should prevent dehydration of the burned tissue, provide a protective effect against the penetration of dust or microorganisms, facilitate gas permeability, and maintain a moist environment. Additionally, it must possess non-adhesive characteristics to prevent secondary damage during removal. Currently used types of dressings include gauze dressings, thin transparent film dressings, calcium alginate dressings, polyurethane foam dressings, hydrofiber dressings, and hydrocolloid dressings.

[0003] Hydrogel dressings and antimicrobial dressings are being used. These dressings are applied to wounds, such as burns, and secured using adhesive tapes, such as bandages, to ensure they adhere well to the wound. Various products currently on the market also utilize adhesive tapes together

[0004] Dressing materials are currently being sold. However, this type of dressing can cause problems upon removal, such as immune reactions to adhesive substances and damage to new granulation tissue. Therefore, there is a need for the development of a treatment kit that can address these issues, is easy to use, and offers excellent burn treatment efficacy. The problem to be solved

[0005] The present invention is intended to solve the problems described above, and the objective of the present invention is to provide a burn treatment kit that is easy to use and has excellent burn treatment effects. The above and other objectives and advantages of the present invention will become apparent from the following description describing preferred embodiments. means of solving the problem

[0007] The above objective can be achieved by a kit for burn treatment that separates and contains component A, which includes isocyanate; and component B, which includes polyol and aluminum hydroxide. Preferably, the isocyanate is 4,4'-Diphenylmethane diisocyanate, hexamethylene diisocyanate, isophorone diisocyanate, toluene-2,6-diisocyanate, toluene-2,4-diisocyanate, 4,4'-Dicyclohexylmethane diisocyanate, trans-1,4-cyclohexane diisocyanate, tetramethyl-1,3-xylene diisocyanate, and dimeryl It may be any one selected from the group consisting of isocyanate (dimeryl diisocyanate) and 1,1,6,6-tetrahydroperfluoro-hexamethylene diisocyanate, or a polymer of any one of them or a mixture thereof.Preferably, the polyol may be any one selected from the group consisting of poly(ethylene oxide), poly(tetramethylene oxide), poly(propylene oxide), polyisobutylene, poly(ethylene adipate), and polycaprolactone, or a polymer of any one of these or a mixture thereof. Preferably, the aluminum hydroxide may be boehmite (

[0012] AlO(OH)). Additionally, it is preferable that the isocyanate be contained in an amount of 15 to 30 parts by weight per 100 parts by weight of the polyol. Furthermore, component B may further include at least one selected from the group consisting of a crosslinking aid, a blowing agent, a surfactant, a catalyst, and an anti-yellowing agent. In this case, the crosslinking aid is 1,3-butane It may be at least one selected from the group consisting of diol (1,3-Butane Diol), 1,4-butane diol (1,4-Butane Diol), 3-methyl-1,5-pentane diol (3-Methyl-1,5-Pentane Diol) and 1,6-hexane diol (1,6-Hexane Diol), and the blowing agent may be water.The surfactant is poly(dimethylsiloxane-co-methyl(3-hydroxypropyl)siloxane)-graft-poly(ethylene glycol)3-aminopropylether, poly(dimethylsiloxane), poly(dimethylsiloxane), bis(3-aminopropyl) terminated, poly(dimethylsiloxane), hydroxy terminated, poly(dimethylsiloxane), bis(hydroxyalkyl) terminated, and It may be at least one selected from the group consisting of poly[dimethylsiloxane-co-[3-(2-(2-hydroxyethoxy)ethoxy)propyl]methylsiloxane]. The catalyst is triethylene diamine, 1,4-diazabicyclo[2.2.2]octane.It may be at least one selected from the group consisting of 2]octane), trimethylaminoethylethanolamine, N,N,N',N',N"-pentamethyldiethylenetriamine, N,N'-dimethylethanolamine, dimethylaminopropylamine, N-ethylmorpholine, N,N-dimethylaminoethylmorpholine, N,N-dimethylcyclohexylamine, 2-methyl-2-azanorbornane and bis(2-dimethylaminoethyl)ether. The anti-yellowing agent may be at least one selected from the group consisting of poly(benzoxazinedione), benzoic acid, 4-hydroxyquinaldic acid, and 2,2'-dihydroxy-4-methoxybenzophenone. Effects of the invention

[0009] According to the present invention, there is no need to provide a separate adhesive tape, making it convenient to use and providing excellent effects in treating burns. However, the effects of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by those skilled in the art from the description below. Specific details for implementing the invention

[0010] The present invention will be described in detail below with reference to embodiments thereof. These embodiments are presented merely as examples to explain the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these embodiments. Furthermore, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art to which the invention pertains, and in the event of a conflict, the description in this specification including definitions shall prevail.

[0024] In order to clearly explain the invention proposed in the drawings, parts unrelated to the description have been omitted, and similar parts throughout the specification have been given similar reference numerals. Also, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. Also, the term "part" as described in the specification refers to a unit or block that performs a specific function. A kit (100) for treating burns according to one embodiment of the present invention comprises a component A (10) containing isocyanate; A component A (10) and a component B (20) including polyol and boehmite (AlO(OH)) are separated and contained so as not to be mixed with each other. That is, as shown in FIG. 1, they are contained by a partition wall (30), and when used, the A component (10) and the B component (20) are mixed to form a polyurethane foam, and then attached to the burn area. At this time, the partition wall (30) can be formed from various materials such as plastic and is not particularly limited. The present invention has the advantage that by immediately mixing and using the A component (10) and the B component (20), the condition of the dressing material (polyurethane foam) is excellent, it can be attached well to the burn area without a separate adhesive tape, and the burn treatment effect is excellent. The A component (10) includes an isocyanate.Isocyanates are key materials for polyurethane foam formation, including 4,4'-Diphenylmethane diisocyanate, Polymeric Methylene Diphenyl Diisocyanate (MDI), Hexamethylene diisocyanate, Isophorone diisocyanate, Toluene-2,6-diisocyanate, Toluene-2,4-diisocyanate, 4,4'-Dicyclohexylmethane diisocyanate, trans-1,4-Cyclohexane diisocyanate, and Tetramethyl-1,3-Xylene It may be any one selected from the group consisting of diisocyanate (Tetramethyl-1,3-xylene diisocyanate), dimeryl diisocyanate, and 1,1,6,6-tetrahydroperfluoro-hexamethylene diisocyanate, or a polymer thereof or a mixture thereof. It is preferable that the isocyanate be contained in an amount of 15 to 30 parts by weight per 100 parts by weight of the polyol to be described later. Component B (20) comprises polyol and boehmite.Polyol is a major material that reacts with the aforementioned isocyanate to form polyurethane foam, and may be any one selected from the group consisting of poly(ethylene oxide), poly(tetramethylene oxide), poly(propylene oxide), polyisobutylene, poly(ethylene adipate), polycaprolactone, polyoxy(propylene) block copolymer, polyoxy(ethylene) block copolymer, and polyether polyol, or a polymer thereof or a mixture thereof. Aluminum hydroxide functions as an antimicrobial agent. That is, after forming polyurethane foam by mixing component A (10) and component B (20), it performs the function of preventing bacterial infection of the burn area when attached to the burn area. It is preferable to use boehmite (AlO(OH)) as the aluminum hydroxide. The boehmite can be γ-boehmite (a), α-boehmite (b), and pseudo-boehmite (c) as shown in the structural formula below. Among these, it is preferable to use γ-boehmite (a), which has excellent crystallinity, resulting in superior thermal and chemical stability, is structurally neutral, exhibits excellent bacterial trapping effects via electrophoresis, and possesses excellent antibacterial properties. γ-boehmite (a) can be prepared by a supercritical synthesis method using only water (pure water) and aluminum (Al), as shown in Chemical Formula 1 below. It is preferable that boehmite be included in an amount of 0.1 to 1.0 parts by weight per 100 parts by weight of polyol. If boehmite is included in an amount less than 0.1 parts by weight, bacteria cannot be effectively blocked, and 1.If included in an amount exceeding 0 parts by weight, there is a concern that it may inhibit the formation of polyurethane foam. Additionally, for improved functionality, component B (20) may further include at least one selected from the group consisting of a crosslinking aid, a foaming agent, a surfactant, a catalyst, and an anti-yellowing agent. The crosslinking aid acts as an intermediate crosslinker during polyurethane foam formation to assist in foam formation and maintenance, and a diol may be used. The diol may be at least one selected from the group consisting of 1,3-butanediol, 1,4-butanediol, 3-methyl-1,5-pentanediol, and 1,6-hexanediol. It is preferable that the crosslinking aid be included in an amount of 0.5 to 2 parts by weight per 100 parts by weight of polyol. If the content of the crosslinking aid is less than 0.5 parts by weight, the formation of the polyurethane foam may not be smooth (foam collapse), and if it exceeds 2 parts by weight, there is a risk that the polyurethane foam will be formed hard. The blowing agent is an aid that helps form the foam by generating gas when component A (10) and component B (20) are mixed to form the polyurethane foam, and water may be used. It is preferable that the blowing agent be included in an amount of 0.5 to 2 parts by weight per 100 parts by weight of polyol. If the blowing agent is less than 0.5 parts by weight, the formation of the polyurethane foam may not be smooth, and if it exceeds 2 parts by weight, excessive gas may be generated, causing the polyurethane foam to burst. The surfactant has the function of making the bubbles generated when component A (10) and component B (20) are mixed to form polyurethane foam smaller, thereby increasing the tactile sensation and absorption capacity (capillary effect) of the formed polyurethane foam.The surfactant is Poly(dimethylsiloxane-co-methyl(3-hydroxypropyl)siloxane)-graft-Poly(ethylene glycol) 3-aminopropylether, Poly(dimethylsiloxane), Poly(dimethylsiloxane), bis(3-aminopropyl) terminated, Poly(dimethylsiloxane), hydroxy terminated, Poly(dimethylsiloxane), bis(hydroxyalkyl) terminated, and It may be at least one selected from the group consisting of poly[dimethylsiloxane-co-[3-(2-(2-hydroxyethoxy)ethoxy)propyl]methylsiloxane]. It is preferable that the surfactant be included in an amount of 0.15 to 0.3 parts by weight per 100 parts by weight of polyol. If the surfactant is less than 0.15 parts by weight, the bubble size may increase, which may result in poor tactile feel and water absorption of the polyurethane foam, and if it exceeds 0.3 parts by weight, it may inhibit the generation of bubbles, thereby reducing the quality of the manufactured polyurethane foam. The catalyst is used to appropriately control the curing time when mixing component A (10) and component B (20), and various known catalysts may be used. Preferably, the catalyst is triethylene diamine, 1,4-diazabicyclo[2.2.2]octane[2.2.It may be at least one selected from the group consisting of 2]octane), trimethylaminoethylethanolamine, N,N,N',N',N"-pentamethyldiethylenetriamine, N,N'-dimethylethanolamine, dimethylaminopropylamine, N-ethylmorpholine, N,N-dimethylaminoethylmorpholine, N,N-dimethylcyclohexylamine, 2-methyl-2-azanorbornane and bis(2-dimethylaminoethyl)ether. It is preferable that the catalyst be included in an amount of 0.2 to 0.5 parts by weight per 100 parts by weight of polyol to control the curing time to approximately 5 minutes. The anti-yellowing agent is used to prevent discoloration, and various known anti-yellowing agents may be used as long as they do not impede the purpose of the present invention. Preferably, the anti-yellowing agent may be at least one selected from the group consisting of poly(benzoxazinedione), benzoic acid, 4-hydroxyquinaldic acid, and 2,2'-dihydroxy-4-methoxybenzophenone. It is preferable that the anti-yellowing agent be used in a minimum amount to achieve the purpose of preventing discoloration, and for this purpose, it is preferable to use 0.1 to 0.2 parts by weight per 100 parts by weight of polyol. If the anti-yellowing agent is less than 0.1 parts by weight, it is difficult to achieve the purpose of preventing discoloration, and 0.If the amount exceeds 2 weight parts, it may degrade the quality of the manufactured polyurethane foam. Below, the composition of the present invention and the resulting effects are to be explained in more detail through specific examples and comparative examples. However, these examples are intended to explain the present invention more specifically, and the scope of the present invention is not limited to these examples. A kit for treating burns (Example) was prepared by accommodating polymeric diphenyl methane diisocyanate (20 parts by weight) as component A, and polypropylene glycols (100 parts by weight), boehmite (AlO(OH), 0.5 parts by weight), 1,3-butanediol (1.0 parts by weight), water (H2O, 1.0 parts by weight), polydimethylsiloxane (0.2 parts by weight), triethylene diamine (0.3 parts by weight), and benzoic acid (0.15 parts by weight) as component B. A burn treatment kit (Comparative Example) was prepared containing Polymeric diphenyl methane diisocyanate (20 parts by weight) as Component A and Polypropylene glycols (100 parts by weight) as Component B. [Control Group] Sterile water for injection (Manufacturing No. 15Q8F21, Daehan Pharmaceutical Co., Ltd.) was used as the control group (excipient). After mixing Components A and B of the Examples and Comparative Examples, the mixture was applied to the burn sites of experimental mice within 4 minutes, and the progress was observed. In addition, the control group was applied for comparison. Statistical analysis was performed using SPSS Statistics 22 for Medical Science, and the results were analyzed using Student's t-test. The groups administered in the Examples and Comparative Examples were compared with the excipient control group, and P<0.In the case of 05, it was determined to be statistically significant. Observation of General Symptoms: During the administration and observation period, the mortality status, type of general symptoms, date of onset, and severity of symptoms were observed once a day and recorded for each individual. The start date of administration was designated as Day 1, and observations were made for 14 days after the administration of the test substance. No adverse symptoms were observed due to the administration of the test substance, and no animals died due to the administration of the test substance. However, one case of death was observed on Day 4 in the comparative example administration group (G3). The cause of death was determined to be respiratory distress caused by compression from the bandage wrapped to protect the site where the test substance was applied. Observation of Body Weight Change: Measured once a week upon entry, upon group separation, and during the experiment period. Burn Induction and Area Measurement (1) Animals were anesthetized by intraperitoneal administration of zoletil at a dose of 1 mg / kg. (2) The dorsal hair was removed with a clipper and disinfected with an alcohol swab. (3) The circular plate (diameter 2 cm) of an aluminum electric soldering iron was preheated to 80°C. (4) Deep second-degree burns were induced by contacting the dorsal surface for approximately 25 seconds at intervals of 1 cm along the spine. (5) Photographs were taken after the burn induction and before the administration of the test substance. Photographs were taken on the day of burn induction (Day 1) and on the days of autopsy (Days 7 and 14). In the case of the Example (G2) and Comparative Example administration group (G3), since the substance had hardened and adhered to the skin, it was carefully removed before photography. (6) To measure the burn area, the photographs taken were analyzed using an image analyzer program (Image pro. Ver 6.3, USA). The experimental results are shown in Table 3 and Figure 3 below. Additionally, photographs of the experimental mice are shown in Figures 4–6 (Figure 4: G1, Figure 5: G2, Figure 6: G3). There was no statistical difference between the example (G2) and comparative example administration group (G3) and the excipient control group (G1). However, on Day 7, the example (G2) and comparative example administration group (G3) showed approximately 3.7 and 5, respectively, compared to the excipient control group (G1).A trend of approximately 9% reduction in burn area was confirmed. On Day 14, the groups administered the Example (G2) and Comparative Example (G3) showed a trend of approximately 23.7% and 9.5% reduction in burn area, respectively, compared to the excipient control group (G1). Autopsy and Histopathological Examination: On the day of autopsy, skin tissue was excised, fixed in a 10% neutral buffered formalin solution, and then histopathological examination was performed using H&E staining. The fixed skin tissue was re-fixed in a 10% neutral buffered formalin fixative for 24 hours, after which a paraffin block was prepared. Slides were prepared by trimming the thickness to approximately 3-4 µm, and hematoxylin and eosin (H&E) and Masson's trichrome (MT) staining were performed. The examination items include epithelium defect length, pustule depth and epithelium marginal thickness, number of infiltrating inflammatory cells and vessels in defect-granulation tissue, and total area.

[0011] Collagen fibers were measured. On Day 7, when the kit for burn treatment according to one embodiment of the present invention was used on experimental mice that had been induced with deep second-degree burns in the pharynx, the epithelium defect length, pustule depth, and the number of infiltrating inflammatory cells and blood vessels in the degenerated granulation tissue were compared with the excipient control group (G1), a significant improvement effect was confirmed in the trend of decreasing burn area and histopathological examination results over time compared to the excipient control group (G1) and comparative example (G3). Based on this, it is determined that the kit for burn treatment according to one embodiment of the present invention is effective for burn treatment. Although this specification describes only a few examples among the various embodiments performed by the inventors, the technical concept of the present invention is not limited or restricted thereto, and it is understood that it can be modified and implemented in various ways by those skilled in the art.

Claims

Claim 1 A kit for treating burns, characterized by separately accommodating component A containing isocyanate; and component B containing polyol and aluminum hydroxide.

Images